A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis

This publication has 52 references indexed in Scilit:

• Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: An EORTC phase iii trial
  European Journal Of Cancer, 1996
• A prospective randomised study in limited disease small cell carcinoma—Doxorubicin and vincristine plus either cyclophosphamide or etoposide
  European Journal Of Cancer, 1995
• Single-agent chemotherapy versus combination chemotherapy in advanced non-small cell lung cancer: a quality and meta-analysis study
  Lung Cancer, 1995
• Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer: a randomised study
  European Journal Of Cancer, 1994
• Randomized Phase II Trial of High-Dose 4’-Epi-Doxorubicin + Cyclophosphamide versus High-Dose 4’-Epi-Doxorubicin + Cisplatin in Previously Untreated Patients with Extensive Small Cell Lung Cancer
  Oncology, 1992
• Etoposide Versus Methotrexate in Small Cell Bronchial Carcinoma a Randomized Study of Two Types of Four-Drug Chemotherapy Regimens
  Acta Oncologica, 1992
• Effective new low toxicity chemotherapy with carboplatin, vinblastine and methotrexate for small cell lung cancer: a randomised trial against doxorubicin, cyclophosphamide and etoposide
  European Journal of Cancer and Clinical Oncology, 1991
• Etoposide compared with the combination of vincristine, doxorubicin, and cyclophosphamide in the treatment of small cell lung cancer.
  Thorax, 1989
• Beta blockade during and after myocardial infarction: An overview of the randomized trials
  Progress in Cardiovascular Diseases, 1985
• A method for assessing the quality of a randomized control trial
  Controlled Clinical Trials, 1981